


# Immune T cell defense is coping with COVID-19 variants of concern (for now)

December 1 2022



CD4<sup>+</sup> T cell response to SARS-CoV-2. **a**, Representative ELISPOT assays for the production of IFN- $\gamma$  in whole and CD8<sup>-</sup> PBMCs isolated from HCW-PI, plated at  $2 \times 10^5$  cells per well and incubated with mixes of 15 aa peptides (overlapping by 11 aa) from SARS-CoV-2 S1, S2, M and N proteins, control (Ctrl) HLA I and HLA II epitope mixes and DMSO solvent (Neg). **b**, Summary of ELISPOT assays for the production of IFN- $\gamma$  in whole versus CD8<sup>-</sup> PBMCs using  $n = 10$  HCW-PI incubated with peptide mixes as in **a**. Results are shown as mean SFC per 10<sup>6</sup> PBMCs. Significance was determined by two-sided Wilcoxon test, \* $P$

Citation: Immune T cell defense is coping with COVID-19 variants of concern (for now) (2022, December 1) retrieved 12 May 2024 from <https://medicalxpress.com/news/2022-12-immune-cell-defense-coping-covid.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.